Biogen Inc (BIIB) Stock Price Today
Aura AI Summary
Key Stats
- $28.34BMarket Cap
- -Volume
- HealthSector
- $216.6352W High
- $122.6852W Low
- -Typical Hold Time
- $30.62BEnterprise Value
- -Div Yield
- -Trading Activity
Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $122.68 and a high of $216.63, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Most Recent News
Japanese firms use NVIDIA Nemotron to build AI tailored for local industries and workforce needs.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint delays annual financial filings due to funding issues, expects to file by Sept 29, 2026.
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Investors in Putnam mutual funds may claim losses in a new class action lawsuit.
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.